A PKA activator
Related Products
Alternative(s)
144318-bromo Cyclic AMP (sodium salt)
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

8-bromo Cyclic AMP

Item No. 18141

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
8-bromo-adenosine cyclic 3',5'-(hydrogen phosphate)
CAS Number
23583-48-4
Synonyms
  • 8-Bromoadenosine 3',5'-cyclic monophosphate
  • 8-bromo cAMP
  • NSC 171719
Molecular Formula
C10H11BrN5O6P
Formula Weight
408.1
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
PBS (pH 7.2): 3 mg/ml
λmax
213, 263 nm
SMILES
OP1(OC[C@]2([H])[C@@]([C@@H](O)[C@H](N3C(N=CN=C4N)=C4N=C3Br)O2)([H])O1)=O
InChi Code
InChI=1S/C10H11BrN5O6P/c11-10-15-4-7(12)13-2-14-8(4)16(10)9-5(17)6-3(21-9)1-20-23(18,19)22-6/h2-3,5-6,9,17H,1H2,(H,18,19)(H2,12,13,14)/t3-,5-,6-,9-/m1/s1
InChi Key
DVKQVRZMKBDMDH-UUOKFMHZSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $62

    Add

    25 mg

    $123

    Add

    50 mg

    $197

    Add

    100 mg

    $304

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    8-bromo Cyclic AMP is an activator of protein kinase A (PKA) with a half-maximal activation (Ka) value of 0.05 µM.1 It is selective for PKA over cGMP-dependent protein kinase (PKG; Ka = 5.8 µM) and is more resistant to hydrolysis by phosphodiesterases (PDEs) compared with cAMP (Item No. 18820).1,2 8-bromo Cyclic AMP inhibits the proliferation of HL-60 leukemia cells (IC50 = 18 µM after six days).2 It induces relaxation of isolated rabbit carotid or renal arterial rings precontracted with phenylephrine when used at concentrations ranging from 10 to 300 µM.3 Intradermal administration of 8-bromo cyclic AMP (10 nmol/site) prevents scratching and increases in cutaneous leukotriene B4 (LTB4) production induced by the proteinase-activated receptor 2 (PAR2) agonist SLIGRL-NH2 (Item No. 16723) in mice.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Sandberg, M., Butt, E., Nolte, C., et al. Characterization of Sp-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole-3',5'-monophosphorothioate (Sp-5,6-DCl-cBiMPS) as a potent and specific activator of cyclic-AMP-dependent protein kinase in cell extracts and intact cells. Biochem. J. 279(Pt 2), 521-527 (1991).

    2. Yokozaki, H., Tortora, G., Pepe, S., et al. Unhydrolyzable analogues of adenosine 3':5'-monophosphate demonstrating growth inhibition and differentiation in human cancer cells. Cancer Res. 52(9), 2504-2508 (1992).

    3. Minonishi, T., Ogawa, K., Tokinaga, Y., et al. Differential vasodilation response to olprinone in rabbit renal and common carotid arteries. J. Anesth. 24(1), 61-66 (2010).

    4. Andoh, T., and Kuraishi, Y. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: Inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP. J. Dermatol. Sci. 76(3), 206-213 (2014).

    Product Citations

    Arai, T., Ono, Y., Arimura, Y., et al. Type I neuregulin1α is a novel local mediator to suppress hepatic gluconeogenesis in mice. Sci. Rep. 7, 42959 (2017).